Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

References

Adjuvant Therapy for Breast Cancer (2000). NIH Consensus Statement, 17, 1-35 and http://consensus.nih.gov.

Anon. (1984). Review of mortality results in randomized trials in early breast cancer. Lancet ii: 1205.

Blanks, R.G., Moss, S.M., McGahan, C.E., Quinn, M.J., Babb, P.J. (2000). Effect of NHS breast screening programme on mortality from breast cancer in England  and Wales, 1990-8: comparison of observed with predicted mortality. British Medical Journal, 321, 665-9.

Darby, S.C., McGale, P., Peto, R., Granath, F., Hall, P., Ekbom, A.(2003). Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90 000 Swedish women. British Medical Journal, 326, 256-257.

Early Breast Cancer Trialists' Collaborative Group (1988). The effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,859 women. New England Journal of Medicine, 319, 1681-1692.

Early Breast Cancer Trialists' Collaborative Group (1990). Treatment of Early Breast Cancer. Volume 1: Worldwide Evidence 1985-1990. Oxford University Press.

Early Breast Cancer Trialists' Collaborative Group (1992). Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet, 339, 1-15 & 71-85.

Early Breast Cancer Trialists' Collaborative Group (1995). Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials. New England Journal of Medicine, 333, 1444-1455.

Early Breast Cancer Trialists' Collaborative Group (1996). Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet, 348, 1189-1196.

Early Breast Cancer Trialists' Collaborative Group (1998a). Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet, 352, 930- 942.

Early Breast Cancer Trialists' Collaborative Group (1998b). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 351, 1451-1467.

Early Breast Cancer Trialists' Collaborative Group (2000). Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet, 355, 1757-1770.

Fisher, B., Redmond, C., Legault-Poisson, S., Dimitrov, N,-V., Brown, A.-M., Wickerham, D.L., Wolmark, N., Margolese, R.G., Bowman, D., Glass, A.G. (1990). Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. Journal of Clinical Oncology, 8,1005-18.

Hotobagyi G.N., Gutterman J.U., and Blumenscein G.R. (1978). Chemoimmunotherapy of advanced breast cancer with BCG. In: Terry WD, Windhurst D, eds. Immunotherapy of cancer: present status of trials in man. New York, Raven Press, pp 155-68.

Peto R. (1996). Five years of tamoxifen — or more?. Journal of the National Cancer Institute, 88, 1791-1793.

Peto, R., Boreham, J., Clarke, M., Davies, C., Beral, V. (2000). UK and USA breast cancer deaths down 25% at ages 20-69 years. Lancet, 355, 1822

Preston, D.L., Shimizu, Y., Pierce, D.A., Suyama, A., Mabuchi, K. (2003) Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality 1950-1997. Radiation Research, 160, 381-407.

Pritchard, K.I., Paterson, A.H., Fine, S., Paul, N.A., Zee, B., Shepherd, L.E., Abu-Zahra, H., Ragaz, J., Knowling, M., Levine, M.N., Verma, S., Perrault, D., Walde, P.L., Bramwell, V.H., Poljicak, M., Boyd, N., Warr, D., Norris, B.D., Bowman, D., Armitage, G.R., Weizel, H., Buckman, R.A. (1997). Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. Journal of Clinical Oncology, 15, 2302-11.

Quinn, M., Babb, P., Brock, A., Kirby, E., Jones, J. (2001). Cancer Trends in England and Wales 1950-99. Studies on Medical and Population Subjects No 66. London: The Stationery Office. Sasieni, P.(2003) Evaluation of the UK breast screening programmes. Annals of Oncology, 14, 1206-8.

Stewart, L. A. and Parmar, M. K. B. (1993). Meta-analysis of the literature or of individual patient data: is there a difference? Lancet, 341, 418-220.

The Early Breast Cancer Trialists’ Collaborative Group: a brief history of results to date [PDF]